PI3K-C2a – kinase-dead
Invented by Bart Vanhaesebroeck
Invented at Ludwig Institute for Cancer Research
- Datasheet
- References (1)
- Inventor Info
Info
| Catalogue Number | 158396 |
| Antigen/Gene or Protein Targets | PIK3C2A |
| Model | Knock-In |
| Production Details | The genomic DNA encoding the ATP-binding DFG motif in the gene encoding PI3K-C2α (Pik3c2a) is mutated to encode the AFG sequence, resulting in the production of a kinase-dead PI3K-C2α protein. |
| Mouse Genetic Background/Cross History | Backcrossed onto C57B6/J for more than 10 generations. |
| Research Area | Cancer |
| Notes | Homozygote mice are lethal between embryonic day 10.5 & 11.5. Heterozygous PI3K-C2α KI mice were viable and fertile, with no significant histopathological findings. However, male heterozygous mice showed early onset leptin resistance, with a defect in leptin signalling in the hypothalamus,correlating with a mild, age-dependent obesity, insulin resistance and glucose intolerance. Insulin signalling was unaffected in insulin target tissues of PI3K-C2α KI mice, in contrast to previous reports in which downregulation of PI3K-C2α in cell lines was shown to dampen insulin signalling. Interestingly, no metabolic phenotypes were detected in female PI3K-C2α KI mice at any age. |
References: 1 entry
References: 1 entry
Inventor Information
Inventors
|
Bart Vanhaesebroeck |
